Satellos Bioscience Inc
XTSX:MSCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Satellos Bioscience Inc
Depreciation & Amortization
Satellos Bioscience Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Satellos Bioscience Inc
XTSX:MSCL
|
Depreciation & Amortization
CA$337k
|
CAGR 3-Years
379%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Depreciation & Amortization
CA$76.9k
|
CAGR 3-Years
134%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Depreciation & Amortization
$19.4m
|
CAGR 3-Years
93%
|
CAGR 5-Years
70%
|
CAGR 10-Years
29%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Depreciation & Amortization
$2.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
32%
|
CAGR 10-Years
9%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Depreciation & Amortization
CA$237.7k
|
CAGR 3-Years
8%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Depreciation & Amortization
$509k
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Satellos Bioscience Inc
Glance View
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-12-01. The firm is engaged in developing therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct dysregulated muscle stem-cell polarity, which balances replenishment of muscle stem cells and production of specialized tissue cells. The company uses MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders. The company also maintains two clinical stage products: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. iCo-008 provides treatment of the dermatological condition bullous pemphigoid (BP), atopic dermatitis, gastrointestinal conditions, and age-related macular degeneration (AMD). Oral Amphotericin B delivery system provides treatment of Visceral Leishmaniasis (VL).
See Also
What is Satellos Bioscience Inc's Depreciation & Amortization?
Depreciation & Amortization
337k
CAD
Based on the financial report for Dec 31, 2022, Satellos Bioscience Inc's Depreciation & Amortization amounts to 337k CAD.
What is Satellos Bioscience Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
70%
Over the last year, the Depreciation & Amortization growth was 103%. The average annual Depreciation & Amortization growth rates for Satellos Bioscience Inc have been 379% over the past three years , 70% over the past five years .
